Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGFβ signaling

Oncogene volume 37, pages 323–331 (2018)Cite this article

Subjects

Abstract

Coactosin-like protein (CLP, or Cotl1), is an F-actin-binding protein, whose role in cancer is largely unknown. Here we show that CLP/Cotl1 is highly expressed in a rat epithelial breast cancer cell line (FE1.3) compared with its mesenchymal counterpart (FE1.2). Knockdown of CLP/Cotl1 in FE1.3 cells increased cell proliferation, whereas its overexpression in FE1.2 cells inhibited proliferation in culture and reduced tumor growth in xenograft assays in mice. Mechanistically, we identified two major pathways through which CLP/Cotl1 exerts its suppressive effects. First, CLP/Cotl1 re-expression in FE1.2 and in human MCF7 breast cancer cells induced expression of the growth-suppressor gene interleukin-24 (IL-24), which independently of p53 upregulates the tumor-suppressor genes p53 apoptosis effector related to PMP-22 (PERP) and p21cip1. Second, overexpression of CLP/Cotl1 potentiated the growth-suppressive effect of transforming growth factor-β1 (TGFβ1), leading to downregulation of TGFβ-responsive genes vascular growth factor A/B (VEGFA/VEGFB), hypoxia inducing factor 1α (HIF-1α) and trombospondin 1 (TSP1), which mediate various hallmarks of cancer progression including angiogenesis, invasion and metastasis. CLP/Cotl1 inhibited TGFβ signaling via a non-canonical signaling involving IL-24-instigated inhibition of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) phosphorylation and subsequent post-transcriptional downregulation of SMAD2 and SMAD4. We also showed that CLP/COTL1 expression sensitizes breast cancer cells to chemotherapeutic drugs, and this was further enhanced by addition of exogenous TGFβ1. CLP/Cotl1 expression is lost in many human malignancies including prostate, uterine and breast cancers. Thus, our results uncover a novel tumor-suppressor role for CLP/Cotl1 and identify the downstream effectors interleukin 24 (IL-24)/PERP and IL-24/MAPK/ERK/TGFβ as potential targets for precision therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Provost P, Doucet J, Stock A, Gerisch G, Samuelsson B, Radmark O . Coactosin-like protein, a human F-actin-binding protein: critical role of lysine-75. Biochem J 2001; 359: 255–263.

    Article  CAS  Google Scholar 

  2. Provost P, Doucet J, Hammarberg T, Gerisch G, Samuelsson B, Radmark O . 5-Lipoxygenase interacts with coactosin-like protein. J Biol Chem 2001; 276: 16520–16527.

    Article  CAS  Google Scholar 

  3. Provost P, Samuelsson B, Radmark O . Interaction of 5-lipoxygenase with cellular proteins. Proc Natl Acad Sci USA 1999; 96: 1881–1885.

    Article  CAS  Google Scholar 

  4. Rakonjac M, Fischer L, Provost P, Werz O, Steinhilber D, Samuelsson B et al. Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production. Proc Natl Acad Sci USA 2006; 103: 13150–13155.

    Article  CAS  Google Scholar 

  5. Wurthner JU, Frank DB, Felici A, Green HM, Cao Z, Schneider MD et al. Transforming growth factor-beta receptor-associated protein 1 is a Smad4 chaperone. J Biol Chem 2001; 276: 19495–19502.

    Article  CAS  Google Scholar 

  6. Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR et al. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol 2003; 21: 566–569.

    Article  CAS  Google Scholar 

  7. Li X, Liu X, Zhao Q, Liu Y, Duan X, Rao Z . Crystallization and preliminary crystallographic studies of human coactosin-like protein (CLP). Acta Crystallogr D Biol Crystallogr 2004; 60: 2387–2388.

    Article  Google Scholar 

  8. Li X, Liu X, Lou Z, Duan X, Wu H, Liu Y et al. Crystal structure of human coactosin-like protein at 1.9 A resolution. Protein Sci 2004; 13: 2845–2851.

    Article  CAS  Google Scholar 

  9. Liu L, Wang Y, Zhang P, Cheng Z, Wan M, Zhou Z et al. Expression, purification and preliminary crystallographic studies of human coactosin-like protein. Acta Crystallogr D Biol Crystallogr 2004; 60: 1651–1653.

    Article  Google Scholar 

  10. Dai H, Wu J, Xu Y, Yajun T, Husheng D, Shi Y . 1H, 13C and 15N resonance assignments and the secondary structures of human coactosin like protein (hCLP) D123N. J Biomol NMR 2004; 29: 455–456.

    Article  CAS  Google Scholar 

  11. Dai H, Huang W, Xu J, Yao B, Xiong S, Ding H et al. Binding model of human coactosin-like protein with filament actin revealed by mutagenesis. Biochim Biophys Acta 2006; 1764: 1688–1700.

    Article  CAS  Google Scholar 

  12. Kim J, Shapiro MJ, Bamidele AO, Gurel P, Thapa P, Higgs HN et al. Coactosin-like 1 antagonizes cofilin to promote lamellipodial protrusion at the immune synapse. PLoS One 2014; 9: e85090.

    Article  Google Scholar 

  13. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K . Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002; 32: 826–836.

    Article  CAS  Google Scholar 

  14. Guo S, Yang P, Jiang X, Li X, Wang Y, Zhang X et al. Genetic and epigenetic silencing of mircoRNA-506-3p enhances COTL1 oncogene expression to foster non-small lung cancer progression. Oncotarget 2017; 8: 644–657.

    PubMed  Google Scholar 

  15. Xuan W, Li YJ, Liu G, Ben-David Y, Archer MC . Interleukin-24 induces expression of beta4 integrin but suppresses anchorage-independent growth of rat mammary tumor cells by a mechanism that is independent of beta4. Mol Cancer Res 2009; 7: 433–442.

    Article  CAS  Google Scholar 

  16. Li YJ, Song R, Korkola JE, Archer MC, Ben-David Y . Cyclin D1 is necessary but not sufficient for anchorage-independent growth of rat mammary tumor cells and is associated with resistance of the Copenhagen rat to mammary carcinogenesis. Oncogene 2003; 22: 3452–3462.

    Article  CAS  Google Scholar 

  17. Menezes ME, Shen XN, Das SK, Emdad L, Guo C, Yuan F et al. MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer. Oncotarget 2015; 6: 36928–36942.

    Article  Google Scholar 

  18. Ihrie RA, Reczek E, Horner JS, Khachatrian L, Sage J, Jacks T et al. Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol 2003; 13: 1985–1990.

    Article  CAS  Google Scholar 

  19. Li YJ, Liu G, Xia L, Xiao X, Liu JC, Menezes ME et al. Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice. Oncotarget 2015; 6: 36943–36954.

    PubMed  PubMed Central  Google Scholar 

  20. Sainz-Perez A, Gary-Gouy H, Gaudin F, Maarof G, Marfaing-Koka A, de Revel T et al. IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression. J Immunol 2008; 181: 6051–6060.

    Article  CAS  Google Scholar 

  21. Su ZZ, Lebedeva IV, Sarkar D, Gopalkrishnan RV, Sauane M, Sigmon C et al. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 2003; 22: 1164–1180.

    Article  CAS  Google Scholar 

  22. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401–404.

    Article  Google Scholar 

  23. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: l1.

    Article  Google Scholar 

  24. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347: 1260419.

    Article  Google Scholar 

  25. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28: 1248–1250.

    Article  CAS  Google Scholar 

  26. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998; 1: 611–617.

    Article  CAS  Google Scholar 

  27. de Caestecker MP, Piek E, Roberts AB . Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000; 92: 1388–1402.

    Article  CAS  Google Scholar 

  28. Nakagawa T, Li JH, Garcia G, Mu W, Piek E, Bottinger EP et al. TGF-beta induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways. Kidney Int 2004; 66: 605–613.

    Article  CAS  Google Scholar 

  29. Gubin MM, Calaluce R, Davis JW, Magee JD, Strouse CS, Shaw DP et al. Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle 2014; 9: 3357–3366.

    Article  Google Scholar 

  30. Tian M, Neil JR, Schiemann WP . Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 2011; 23: 951–962.

    Article  CAS  Google Scholar 

  31. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 2013; 123: 1348–1358.

    Article  CAS  Google Scholar 

  32. Luo K . Signaling cross talk between TGF-beta/Smad and other signaling pathways. Cold Spring Harb Perspect Biol 2017; 9: pii: a022137.

  33. Sun W, Guo C, Meng X, Yu Y, Jin Y, Tong D et al. Differential expression of PAI-RBP1, C1orf142, and COTL1 in non-small cell lung cancer cell lines with different tumor metastatic potential. J Investig Med 2012; 60: 689–694.

    Article  CAS  Google Scholar 

  34. Wylie-Sears J, Levine RA, Bischoff J . Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-beta-induced phosphorylation of ERK. Biochem Biophys Res Commun 2014; 446: 870–875.

    Article  CAS  Google Scholar 

  35. Li CY, Suardet L, Little JB . Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 1995; 270: 4971–4974.

    Article  CAS  Google Scholar 

  36. Menezes ME, Bhatia S, Bhoopathi P, Das SK, Emdad L, Dasgupta S et al. MDA-7/IL-24: multifunctional cancer killing cytokine. Adv Exp Med Biol 2014; 818: 127–153.

    Article  CAS  Google Scholar 

  37. Wang CJ, Zhang H, Chen K, Zheng JW, Xiao CW, Ji WW et al. Ad.mda-7 (IL-24) selectively induces apoptosis in hepatocellular carcinoma cell lines, suppresses metastasis, and enhances the effect of doxorubicin on xenograft tumors. Oncol Res 2010; 18: 561–574.

    Article  Google Scholar 

  38. Xia L, Plachynta M, Liu T, Xiao X, Song J, Li X et al. Pro-inflammatory effect of a traditional Chinese medicine formula with potent anti-cancer activity in vitro impedes tumor inhibitory potential in vivo. Mol Clin Oncol 2016; 5: 717–723.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by research grants from the National Natural Science Foundation of China (81472609), the Science and Technology Department of Guizhou Province Innovation and Project Grant (2013-6012) and Thousand Talent Program of China (WQ20135200171) and to YBD.

Author information

Author notes

  1. L Xia and X Xiao: Equal contribution by the first authors.

Authors and Affiliations

  1. State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, PR China

    L Xia, X Xiao, W L Liu, Y Song, T J J Liu, X J Hao & Y Ben-David

  2. The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, PR China

    L Xia, X Xiao, W L Liu, Y Song, T J J Liu, X J Hao & Y Ben-David

  3. School of Pharmaceutical Sciences, Guizhou University, Guizhou, China

    L Xia & X J Hao

  4. Department of Anatomy, Norman Bethune College of Medicine, Jilin University, Changchun, China

    Y J Li

  5. Department of Medicine, University of Toronto, Toronto, Ontario, Canada

    E Zacksenhaus

  6. Division of Advanced Diagnostics, Toronto General Research Institute—University Health Network, Toronto, Ontario, Canada

    E Zacksenhaus

Authors
  1. L Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W L Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T J J Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y J Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Zacksenhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. X J Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y Ben-David
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Ben-David.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xia, L., Xiao, X., Liu, W. et al. Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGFβ signaling. Oncogene 37, 323–331 (2018). https://doi.org/10.1038/onc.2017.342

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2017.342

This article is cited by

Search

Advanced search

Quick links